Cutia Therapeutics (HKG:2487) said the Phase III clinical trial in China of CU-40102, a topical finasteride spray, and CU-30101, a localized topical lidocaine and tetracaine cream, was presented through electronic posters at the 19th Annual Meeting of China Dermatologist Association & National Congress of Cosmetic Dermatology, according to a Thursday filing with the Hong Kong bourse.

Topical finasteride spray is used for the treatment of androgenetic alopecia, also known as male pattern baldness. CU-30101 is used for localized topical lidocaine and tetracaine cream for surface dermatologic issues, the filing said.